Enter your email address below and subscribe to our newsletter

Clinical Trial

Share your love

2023 Recap: Top 15 Firsts in Ophthalmology

In a year marked by groundbreaking achievements, the field of ophthalmology witnessed a series of historic firsts, pushing the boundaries of innovation and patient care. Here are the noteworthy milestones: Pioneering the integration of technology into glaucoma management, the world’s…

Aviceda’s IND Cleared by FDA for GA to AMD Treatment

Aviceda Therapeutics announced that the FDA has granted clearance for the IND for AVD-104. This clearance will allow the company to proceed with the initiation of Phase 2 clinical trials of its leading intravitreal ocular asset for the treatment of…

FDA Calls for Study on Aldeyra’s Reproxalap in DED

Aldeyra Therapeutics announced the receipt of a Complete Response Letter from the U.S. Food and Drug Administration (FDA) in response to the New Drug Application (NDA) for reproxalap, an investigational drug candidate designed for the treatment of dry eye disease.…

Reviving Hope for Amblyopia: Late-Stage Treatment

In children with amblyopia, often referred to as “lazy eye,” one eye exhibits weaker vision than the other due to various factors. This weaker eye may struggle with focusing, misalignment due to strabismus, or vision obstruction from conditions like cataracts…

UCL-Moorfields Eye Hospital Secures £5M for Research Center

The Sir Jules Thorn Charitable Trust has allocated £5 million towards the establishment of a  research center within Oriel, the collaborative initiative between UCL and Moorfields Eye Hospital aimed at advancing eye health. Partnering with Moorfields Eye Charity and Moorfields…

New Experimental Drug Shows Promise in Treating DME

A recent study published in Nature Medicine has unveiled promising insights into a potential breakthrough in the treatment of Diabetic Macular Edema (DME). The study suggests that an experimental drug, part of a new class of therapeutics called “senolytics,” could…

Perfluorohexyloctane Drops Help Alleviate Dry Eye

According to recent research, perfluorohexyloctane eye drops (SHR8058) demonstrated significant improvement in both the signs and symptoms of dry eye disease (DED) linked to meibomian gland dysfunction (MGD) with rapid effectiveness in Chinese patients. The findings showed that the perfluorohexyloctane…

Treatment of Intraocular Melanoma | OBN

Melanoma of the uveal tract (iris, ciliary body, and choroid), though rare, is the most common primary intraocular malignancy in adults. The mean age-adjusted incidence of uveal melanoma in the United States is approximately 4.3 new cases per million people,…

4DMT Reports Positive Interim Data for Wet AMD Treatment

4D Molecular Therapeutics (4DMT) announced positive interim data from the Phase 2 PRISM clinical trial, marking a significant stride in the treatment of wet age-related macular degeneration (wet AMD). Arshad M. Khanani, MD, MA, FASRS, presented the data at the…

Kiora, Théa Partner for Retinal Disease Treatment

Kiora Pharmaceuticals has joined forces with Théa Open Innovation (TOI), a sister company of Laboratoires Théa, to develop and commercialize KIO-301 for the treatment of degenerative retinal diseases. The strategic agreement grants Théa exclusive worldwide development and commercialization rights, excluding…

Stay informed and not overwhelmed, subscribe now!